<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Fifty consecutive patients, 30 of whom had <z:mp ids='MP_0002872'>polycythaemia</z:mp> vera (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e>), 10 essential <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">thrombocythaemia</z:e> (ET), and 10 <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> (MF), entered a long-term prospective study of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> (HU) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The indication for treatment was mainly <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> or symptomatic <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Control of <z:hpo ids='HP_0001901'>erythrocytosis</z:hpo> and <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo> was achieved in 70% of the patients </plain></SENT>
<SENT sid="3" pm="."><plain>Continuous maintenance treatment was required </plain></SENT>
<SENT sid="4" pm="."><plain>In 15% of responding patients with <z:hpo ids='HP_0001894'>thrombocytosis</z:hpo>, unexpected rises of the platelet count occurred during maintenance therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Severe thrombo-embolic events occurred in 6 patients </plain></SENT>
<SENT sid="6" pm="."><plain>The size of the spleen decreased in <z:hpo ids='HP_0000001'>all</z:hpo> patients who did not develop <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> and could absorb adequate HU doses </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (AL) was diagnosed in 9 patients and a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> in one </plain></SENT>
<SENT sid="8" pm="."><plain>Seven of them had been treated with HU alone </plain></SENT>
<SENT sid="9" pm="."><plain>Among the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and ET, 6 developed AL and 4 of them were treated with HU alone (3 PV and 1 ET), giving an incidence of 10.5% </plain></SENT>
<SENT sid="10" pm="."><plain>In previously untreated patients with initially <z:mpath ids='MPATH_458'>normal</z:mpath> karyotypes (n = 19), chromosome abnormalities developed during HU therapy in 7 (37%) </plain></SENT>
<SENT sid="11" pm="."><plain>Our results indicate that HU should be regarded as leukaemogenic, at least when used for treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and allied diseases </plain></SENT>
<SENT sid="12" pm="."><plain>Since myelosuppressive treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> does not prolong survival, the use of HU should be restricted to patients in whom the treatment indication outweights the risk of <z:mpath ids='MPATH_336'>leukaemia</z:mpath> induction </plain></SENT>
</text></document>